Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (221-230 of 499) with videos related to

Pageof 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy, Josep Tabernero, Chris Twelves, et al.
International Journal of Cancer|May 15, 2018
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerEric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, et al.
Acta Oncologica (Stockholm, Sweden)|December 2, 2015
Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survivalGeert Maleux, Christophe Deroose, Annouschka Laenen, et al.
Future Oncology (London, England)|May 10, 2022
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancerYelena Y Janjigian, Eric Van Cutsem, Kei Muro, et al.
Annals of Surgery|October 31, 2007
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891Hans G Smeenk, Casper H J van Eijck, Wim C Hop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trialEric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trialsGunnar Folprecht, Matthew T Seymour, Leonard Saltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyAtsushi Ohtsu, Manish A Shah, Eric Van Cutsem, et al.
Future Oncology (London, England)|May 9, 2025
A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON studyScott Kopetz, Danielle A Murphy, Jie Pu, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2018
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018Deepak B Vangala, Estelle Cauchin, Judith Balmaña, et al.
Pageof 50

Showing results (221-230 of 499) with videos related to

Sort By:
Pageof 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy, Josep Tabernero, Chris Twelves, et al.
International Journal of Cancer|May 15, 2018
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerEric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, et al.
Acta Oncologica (Stockholm, Sweden)|December 2, 2015
Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survivalGeert Maleux, Christophe Deroose, Annouschka Laenen, et al.
Future Oncology (London, England)|May 10, 2022
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancerYelena Y Janjigian, Eric Van Cutsem, Kei Muro, et al.
Annals of Surgery|October 31, 2007
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891Hans G Smeenk, Casper H J van Eijck, Wim C Hop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trialEric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trialsGunnar Folprecht, Matthew T Seymour, Leonard Saltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyAtsushi Ohtsu, Manish A Shah, Eric Van Cutsem, et al.
Future Oncology (London, England)|May 9, 2025
A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON studyScott Kopetz, Danielle A Murphy, Jie Pu, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2018
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018Deepak B Vangala, Estelle Cauchin, Judith Balmaña, et al.
Pageof 50